Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428719 | 0.92 | LMNA (0.48) | LMNAKDM4EL3MBTL1EPHX1ACP3 | |
| SCHEMBL4355212 | 0.84 | LMNA (0.58) | LMNAKDM4EL3MBTL1CYP1A2EPHX1 | |
| SCHEMBL125923 | 0.84 | LMNA (0.58) | LMNAKDM4EL3MBTL1CYP1A2EPHX1 | |
| SCHEMBL317160 | 0.82 | PPARG (0.44) | LMNAKDM4EL3MBTL1ACP3SLC6A2 | |
| SCHEMBL27637997 | 0.81 | KCNH2 (0.41) | LMNATRPA1MAOASLC6A3 | |
| SCHEMBL12816986 | 0.81 | MTNR1A (0.43) | CYP1A2EPHX1MAOASLC6A2SLC6A4 | |
| SCHEMBL8202062 | 0.81 | TRPA1 (0.46) | CYP1A2EPHX1TRPA1ALPIPKM | |
| SCHEMBL27550952 | 0.81 | LMNA (0.50) | LMNAKDM4EL3MBTL1AOC3SLC6A2 | |
| SCHEMBL27930422 | 0.81 | SLC6A2 (0.59) | CYP1A2EPHX1ACP3MAOASLC6A2 | |
| SCHEMBL1403749 | 0.79 | EPHX1 (0.41) | LMNAKDM4EL3MBTL1CYP1A2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | claimed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | claimed |
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-2257548-B1 | THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-7956051-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | claimed |
| EP-2247583-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2010-11-10 | — | — | EP | claimed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | claimed |
| EP-2121609-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2009094286-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-07-30 | — | — | US | claimed |
| WO-2008091818-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| CN-105520941-B | Substituted gamma lactams as therapeutic agents | 阿勒根公司 | 2020-05-01 | — | — | CN | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2027081-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2285775-B1 | Lactams and their use in the treatment of inter alia ocular hypertension or baldness | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2007115020-A2 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007109578-A2 | SUBSTITUTED GAMMA LACTAMS AS PROSTAGLANDIN EP2 AGONISTS | ALLERGAN, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2006121708-A1 | SUBSTITUTED BETA-LACTAMS AND THEIR USE IN MEDICINE | ALLERGAN, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | LMNA 3131/4885KDM4E 2381/4885L3MBTL1 3994/4885 |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | VIP, SHH, GLI1 | LMNA 3937/4885KDM4E 1468/4885L3MBTL1 4695/4885 |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | LMNA 2238/4885KDM4E 3314/4885L3MBTL1 3570/4885 |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | LMNA 2522/4885KDM4E 2953/4885L3MBTL1 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.